Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.
1. A polymorph of a tosylate salt of Compound 1:
selected from the group consising of:
a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 8.06, 13.02, and 18.83 °2θ using Cu Kα radiation,
a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11 and 15.60 °2θ using Cu Kα radiation, and
a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 11.88 and 16.12 °2θ using Cu Kα radiation.
2. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 °2θ using Cu Kα radiation.
3. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54, and 24.53 °2θ using Cu Kα radiation.
4. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 8 .
5. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11, 8.89, 10.34, 11.76, and 15.60 °2θ using Cu Kα radiation.
6. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11, 8.89, 10.34, 11.76, 13.70, 14.81, and 15.60 °2θ using Cu Kα radiation.
7. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 10 .
8. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 7.82, 11.88, 16.12, and 21.46 °2θ using Cu Kα radiation.
9. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern including peaks at approximately 7.82, 11.88, 12.68, 16.12, 18.63, 21.46, and 23.74 °2θ using Cu Kα radiation.
10. The polymorph of claim 1 , characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 9 .
11. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1:
from isopropanol.
12. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1:
from a ketone.
13. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1:
from acetone, methyl ethyl ketone or methyl pentanone.
14. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1:
from ethyl acetate.
15. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1:
from dichloromethane.
16. A pharmaceutical composition comprising the polymorph of claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.
17. The pharmaceutical composition of claim 16 , wherein the polymorph is in a pure form.